Nurix Therapeutics (NRIX) Interest & Investment Income (2019 - 2026)
Nurix Therapeutics (NRIX) posted quarterly Interest & Investment Income of $4.4 million for Q2 2026, down 21.72% year-over-year from $5.6 million in Q2 2025, and down 17.35% quarter-over-quarter from $5.3 million in Q1 2026.
Powered by 
Analysis
Nurix Therapeutics (NRIX) Interest & Investment Income (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has reported Interest & Investment Income for 8 consecutive years, with $4.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest & Investment Income fell 21.72% year-over-year to $4.4 million; the TTM figure through May 2026 stood at $19.6 million (down 18.46% YoY), while the FY2025 annual figure was $22.0 million, up 11.36% from the prior year.
- Interest & Investment Income fell to $4.4 million in Q2 2026 per NRIX's latest filing, from $5.3 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $6.5 million in Q1 2025 and bottomed at $211000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $3.7 million across 5 years, with a median of $3.9 million in 2024.
- On a YoY basis, Interest & Investment Income climbed as much as 2487.18% in 2022 and fell as far as 33.65% in 2022.
- Nurix Therapeutics' Interest & Investment Income stood at $2.0 million in 2022, then jumped by 71.21% to $3.4 million in 2023, then jumped by 81.05% to $6.1 million in 2024, then retreated by 20.31% to $4.9 million in 2025, then fell by 9.77% to $4.4 million in 2026.
- Business Quant data shows NRIX's Interest & Investment Income at $4.4 million in Q2 2026, $5.3 million in Q1 2026, and $4.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Nurix Therapeutics | 2.86 Bn | 2.41 Bn | - | 4.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | 4.40 Mn |
| Feb 28, 2026 | 5.32 Mn |
| Nov 30, 2025 | 4.87 Mn |
| Aug 31, 2025 | 4.96 Mn |
| May 31, 2025 | 5.62 Mn |
| Feb 28, 2025 | 6.51 Mn |
| Nov 30, 2024 | 6.12 Mn |
| Aug 31, 2024 | 5.74 Mn |
| May 31, 2024 | 4.08 Mn |
| Feb 29, 2024 | 3.79 Mn |
| Nov 30, 2023 | 3.38 Mn |
| Aug 31, 2023 | 3.03 Mn |
| May 31, 2023 | 2.49 Mn |
| Feb 28, 2023 | 2.22 Mn |
| Nov 30, 2022 | 1.97 Mn |
| Aug 31, 2022 | 1.01 Mn |
| May 31, 2022 | 314,000.00 |
| Feb 28, 2022 | 211,000.00 |
| Nov 30, 2021 | 295,000.00 |
| Aug 31, 2021 | 39,000.00 |